PMC10407267_01
The clinical course of the present case, including eosinophil count, blood total IgE antibody, FeNO, FEV1, PSL use, and mepolizumab use. After initiation of PSL, eosinophil count, and FeNO decreased and FEV1 increased. After starting the mepolizumab combination, PSL was gradually reduced, but eosinophils remained decreased and FEV1 remained increased. FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; PSL, prednisolone.
gr1.jpg
PMC10407267_01_gr1.jpg
fig1
Mepolizumab 100 mg/4 weeks was introduced on day 21 of admission (Fig. 1). Chest radiography and CT scans also showed no deterioration (Figs. 1 and 2, Fig. 3).
Chest X-ray images of the patient. (A) At the time of the first presentation to our hospital; (B) 1 month after starting prednisolone; (C) 4 months after starting prednisolone (prednisolone was discontinued); (D) 7 months after starting prednisolone (3 months after stopping prednisolone).
gr2.jpg
PMC10407267_01_gr2.jpg
fig2
Chest radiography and CT scans also showed no deterioration (Figs. 1 and 2, Fig. 3).